BioMarin Pharmaceutical Inc. (BMRN) CEO Sells $262,740.00 in Stock

Share on StockTwits

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 3,000 shares of the firm’s stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $87.58, for a total value of $262,740.00. Following the sale, the chief executive officer now owns 291,290 shares of the company’s stock, valued at $25,511,178.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Thursday, January 10th, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $90.55, for a total value of $271,650.00.
  • On Saturday, December 28th, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $84.04, for a total value of $252,120.00.
  • On Friday, December 28th, Jean Jacques Bienaime sold 3,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $84.04, for a total value of $252,120.00.
  • On Wednesday, December 26th, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $80.50, for a total value of $322,000.00.
  • On Friday, December 14th, Jean Jacques Bienaime sold 2,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $92.64, for a total value of $185,280.00.
  • On Wednesday, December 12th, Jean Jacques Bienaime sold 2,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $93.12, for a total value of $186,240.00.
  • On Thursday, November 1st, Jean Jacques Bienaime sold 4,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $92.55, for a total value of $370,200.00.

BioMarin Pharmaceutical stock opened at $94.46 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.26 and a current ratio of 2.87. BioMarin Pharmaceutical Inc. has a 12-month low of $75.81 and a 12-month high of $106.74. The firm has a market cap of $16.18 billion, a P/E ratio of -140.99 and a beta of 1.57.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, October 25th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.15. BioMarin Pharmaceutical had a negative net margin of 8.35% and a negative return on equity of 2.98%. The firm had revenue of $391.71 million during the quarter, compared to analyst estimates of $369.43 million. On average, equities research analysts expect that BioMarin Pharmaceutical Inc. will post -0.13 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of the business. Nordea Investment Management AB boosted its position in BioMarin Pharmaceutical by 2.1% during the third quarter. Nordea Investment Management AB now owns 7,206 shares of the biotechnology company’s stock worth $699,000 after purchasing an additional 147 shares during the period. State of Alaska Department of Revenue raised its stake in BioMarin Pharmaceutical by 0.8% in the fourth quarter. State of Alaska Department of Revenue now owns 21,807 shares of the biotechnology company’s stock valued at $1,856,000 after purchasing an additional 175 shares in the last quarter. Morningstar Investment Services LLC raised its stake in BioMarin Pharmaceutical by 11.8% in the third quarter. Morningstar Investment Services LLC now owns 5,058 shares of the biotechnology company’s stock valued at $490,000 after purchasing an additional 532 shares in the last quarter. Comerica Bank raised its stake in BioMarin Pharmaceutical by 5.9% in the third quarter. Comerica Bank now owns 10,096 shares of the biotechnology company’s stock valued at $1,012,000 after purchasing an additional 565 shares in the last quarter. Finally, Virtus ETF Advisers LLC grew its position in BioMarin Pharmaceutical by 7.2% during the third quarter. Virtus ETF Advisers LLC now owns 8,700 shares of the biotechnology company’s stock valued at $844,000 after acquiring an additional 586 shares during the last quarter.

Several research analysts have issued reports on BMRN shares. Zacks Investment Research cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, December 31st. Oppenheimer assumed coverage on shares of BioMarin Pharmaceutical in a research note on Thursday, December 13th. They issued a “hold” rating and a $92.00 price objective for the company. Raymond James boosted their target price on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a research report on Friday, October 26th. Canaccord Genuity boosted their target price on shares of BioMarin Pharmaceutical from $113.00 to $116.00 and gave the stock a “buy” rating in a research report on Tuesday, October 23rd. Finally, Guggenheim initiated coverage on shares of BioMarin Pharmaceutical in a research report on Monday, December 17th. They set a “neutral” rating for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and sixteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $113.38.

TRADEMARK VIOLATION NOTICE: “BioMarin Pharmaceutical Inc. (BMRN) CEO Sells $262,740.00 in Stock” was reported by Macon Daily and is owned by of Macon Daily. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://macondaily.com/2019/01/12/biomarin-pharmaceutical-inc-bmrn-ceo-sells-262740-00-in-stock.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

See Also: Short Selling Stocks, A Beginner’s Guide

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply